| Literature DB >> 28272397 |
Gui-Yang Xia1,2, De-Juan Sun2, Jiang-Hao Ma2, Yue Liu2, Feng Zhao3, Paul Owusu Donkor1, Li-Qin Ding1, Li-Xia Chen2, Feng Qiu1.
Abstract
Germacrane-type sesquiterpenes, with a flexible 10-membered ring unit as the structural and conformational features, play a central role in the biosynthesis and synthesis of other sesquiterpenes. In this report, two pairs of new sesquiterpene alkaloids, (+)/(-)-phaeocaulin A [(+)-1/(-)-1] and B [(+)-2/(-)-2], and two pairs of new sesquiterpenes, (+)/(-)-phaeocaulin C [(+)-3/(-)-3] and D [(+)-4/(-)-4], along with one related known analog (5), were isolated from the rhizomes of Curcuma phaeocaulis. The absolute configurations of (+)-1/(-)-1, (+)-2/(-)-2, (+)-3/(-)-3 and (+)-4/(-)-4 were unambiguously determined by analysis of single-crystal X-ray diffractions and quantum chemical electronic circular dichroism (ECD) method. It is noteworthy that (+)/(-)-phaeocaulin A [(+)-1/(-)-1] and B [(+)-2/(-)-2] are two pairs of rare N-containing germacrane-type sesquiterpenes. A possible biogenetic pathway for 1-5 was postulated. All of the isolated compounds were tested for their inhibitory activity against LPS-induced nitric oxide production in RAW 264.7 macrophages.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28272397 PMCID: PMC5341095 DOI: 10.1038/srep43576
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Chemical structures of (+)-1/(−)-1, (+)-2/(−)-2, (+)-3/(−)-3 and (+)-4/(−)-4.
1H NMR (600 MHz) and 13C NMR data for compounds 1–4 (δ in ppm, J in Hz).
| Position | 1 | 2 | 3 | 4 | ||||
|---|---|---|---|---|---|---|---|---|
| 1H | 13C | 1H | 13C | 1H | 13C | 1H | 13C | |
| 1 | 4.92 (dd, 10.6, 3.6) | 128.4 | 4.90 (m) | 129.2 | 5.01 (brs) | 128.7 | 5.27 (d, 7.9) | 130.7 |
| 2 | 2.06 (m) | 26.9 | 2.16 (m) | 28.4 | 2.16 (m) | 27.0 | 2.14 (m) | 29.3 |
| 2.20 (ddd, 24.0, 12.0, 3.3) | 2.16 (m) | 2.16 (m) | 2.22 (m) | |||||
| 3 | 2.89 (m) | 31.0 | 3.00 (m) | 32.6 | 3.01 (m) | 30.8 | 2.40 (m) | 36.2 |
| 2.11 (m) | 2.10 (m) | 2.14 (m) | 2.12 (m) | |||||
| 4 | 148.7 | 151.4 | 150.6 | 140.3 | ||||
| 5 | 6.37 (s) | 130.9 | 6.30 (s) | 130.6 | 6.17 (brs) | 127.7 | 3.45 (s) | 50.7 |
| 6 | 195.3 | 196.0 | 191.1 | 197.1 | ||||
| 7 | 153.7 | 156.3 | 158.1 | 154.7 | ||||
| 8 | 92.8 | 4.64 (d, 9.8) | 60.4 | 5.24 (brs) | 80.1 | 110.4 | ||
| 9 | 2.24 (d, 12.8) | 50.3 | 2.63 (dd, 11.8, 3.1) | 47.3 | 2.86 (dd, 11.8, 3.7) | 45.5 | 2.32 (d, 13.3) | 49.9 |
| 2.69 (d, 12.8) | 1.96 (m) | 2.18 (m) | 2.86 (d, 13.3) | |||||
| 10 | 139.4 | 138.1 | 133.6 | 135.4 | ||||
| 11 | 140.3 | 140.9 | 132.9 | 130.5 | ||||
| 12 | 172.1 | 175.1 | 172.9 | 170.4 | ||||
| 13 | 1.93 (s) | 10.1 | 1.91 (s) | 10.8 | 2.03 (s) | 9.9 | 2.00 (s) | 10.6 |
| 14 | 1.88 (s) | 25.2 | 1.92 (s) | 25.9 | 1.93 (s) | 25.0 | 4.95 (s) | 119.2 |
| 5.12 (s) | ||||||||
| 15 | 1.66 (s) | 18.8 | 1.61 (s) | 17.7 | 1.60 (s) | 16.6 | 1.64 (s) | 17.8 |
aSpectra were obtained in CD3OD.
bSpectra were obtained in CDCl3.
cRecorded at 75 MHz.
dRecorded at 150 MHz.
Figure 2Key HMBC correlations of compounds 1, 2, 3 and 4.
Figure 3Experimental ECD spectra of compounds (+)-1/(−)-1, (+)-2/(−)-2, (+)-3/(−)-3 and (+)-4/(−)-4 and calculated ECD spectra of 8S/8R of 1–4.
Figure 4ORTEP drawings of compounds (−)-1, (+)-3, and (−)-3.
NO inhibitory activity of compounds 1–5.
| Compounds | IC50 ± SD(μM) | Compounds | IC50 ± SD(μM) |
|---|---|---|---|
| (±)- | 57.63 ± 4.44 | (±)- | 28.72 ± 2.80 |
| (+)- | 35.97 ± 3.13 | (+)- | 20.43 ± 2.26 |
| (−)- | 57.25 ± 4.27 | (−)- | 23.85 ± 2.20 |
| (±)- | 44.18 ± 3.91 | (±)- | 29.17 ± 2.78 |
| (+)- | 24.02 ± 1.99 | (±)- | 17.34 ± 1.65 |
| (−)- | 47.95 ± 3.68 | 48.66 ± 3.26 |
Characteristic features for the enantiomers.
| (+)-1 | (−)-1 | (+)-2 | (−)-2 | (+)-3 | (−)-3 | (+)-4 | (−)-4 | ||
|---|---|---|---|---|---|---|---|---|---|
| C-8 | |||||||||
| Retention time (min) | 7.0 | 15.4 | 9.7 | 10.9 | 10.8 | 12.2 | 9.7 | 11.1 | |
| Optical rotation | +25.7 | −32.9 | +43.1 | −32.0 | +68.0 | −46.3 | +106.7 | −88.9 | |
| CEs | 200–205 nm | + | − | + | − | + | − | + | − |
| 220–260 nm | − | + | − | + | − | + | + | − | |
| 280–310 nm | + | − | + | − | + | − | − | + | |
aFor chromatographic conditions, see extraction and isolation section.
Figure 5Plausible biogenetic pathway of 1–5.